This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Leena Bruckner-Tuderman, MD; Christian Sigg, MD; Jean-Marie Geiger, MD; Stefano Gilardi, MD

Arch Dermatol. 1988;124(4):529-532.

Abstract
• Eight men with severe recessive x-linked ichthyosis were treated with acitretin, the main metabolite of etretinate, during four months. All of the patients showed marked clinical improvement of scaling during therapy. Hypervitaminosis A-type adverse reactions were observed in all patients. Although the overall tolerance was good, therapy was interrupted in one atopic patient because of pruritus. There were no undesirable laboratory changes in values. Thirty-five milligrams of acitretin daily provided the best efficacy, with minimal side effects. The beneficial effect of this retinoid lasted between four and six weeks after therapy was stopped. These results suggest that acitretin is a useful agent in the symptomatic therapy of severe recessive x-linked ichthyosis resistant to topical therapeutic modalities. Good results with this agent can be achieved with interval therapy adjusted to seasonal variations of the skin symptoms.

(Arch Dermatol 1988;124:529-532)

Author Affiliations
From the Department of Dermatology, University Hospital, Zurich (Drs Bruckner-Tuderman, Sigg, and Gilardi), and the Department of Clinical Research-Dermatology, Hoffmann-La Roche & Co Ltd, Basel, Switzerland (Dr Geiger).

Footnotes
Accepted for publication Oct 20, 1987.

Reprint requests to Department of Dermatology, University of Zurich, Gloriastr 31, 8091 Zurich, Switzerland (Dr Bruckner-Tuderman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?